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ALTttOUGH basic mechanisms of bronchial hyper-respon-
siveness (BHR) are still incompletely understood, inflam-
mation of airways is likely to play a fundamental role in
modulating BHR in patients with asthma. The involve-
ment of several inflammatory cells (eosinophils, mast
cells, lymphocytes, neutrophils, macrophages and plate-
lets) and ofbioactive mediators secreted by these cells in
the pathogenesis of asthma is well documented. Sodium
cromoglycate and nedocromil sodium are two pharmaco-
logical agents which have anti-allergic and anti-inflam-
matory properties. Their clinical effectiveness in mild to
moderate asthma, and the capacity to reduce BHR under
different natural and experimental conditions, make
them valuable drugs for maintenance therapy in patients
with asthma.
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Bronchial Hyper-responsiveness
Bronchial hyper-responsiveness (BHR) is defined
as an abnormal responsiveness of the airways which
determines an increased air flow obstruction on
exposure to different stimuli. Classically, these
stimuli have been divided into specific stimuli such
as allergens and chemicals, and non-specific stimuli
such as histamine, methacholine, cold air and exer-
cise. Nevertheless, this classification does not seem
completely adequate since the so-called non-specific
stimuli also act through different and specific mecha-
nisms. Although some authors feel that BHR is
acquired during life, there is evidence that constitu-
tional and familial or genetic factors play a major
role in predisposing to BHR. The risk of BHR is
related to the degree and the severity of atopy. In
allergic asthmatics, BHR increases during prolonged
exposition to inhaled allergens (e.g. during the
pollen season) and significantly decreases after
adequate environmental control.6,7 There is also a
strong association between the degree of BHR and
asthma severity and medication requirement, and
BHR is considered to be a risk factor for the outcome
of childhood asthma.
Although the factors that may contribute to BHR
are still incompletely known, there is today strong
evidence that the inflammatory process that occurs in
the airways in asthma is the key event in the modu-
lation of BHR. Studies on bronchial alveolar lavage
(BAD, sputum or bronchial biopsies in subjects with
asthma are all consistent with the involvement of
eosinophils, mast cells, lymphocytes, neutrophils,
macrophages and platelets in airway inflammation,
Consequently, a variety of inflammatory mediators
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are locally active, such as histamine, prostanoids,
leukotrienes, kinins, eosinophil proteins, mast cell
tryptase and neuropeptides.
11 The role of mast cells
seems to be of the greatest importance in the initial
phases of allergic inflammation. Two populations of
these cells have so far been identified in human
lungs. One is located near blood vessels and fibrous
stroma, and can be studied only after enzymatic
dissociation of whole lung tissue. The second popu-
lation is between the basement membrane and the
epithelium, and can be easily recovered in BAL. The
two types of pulmonary mast cells show subtle func-
tional differences, and they probably play distinct
roles in the pathogenesis of asthma. 12,13 Because of
their location, BAL mast cells would come into imme-
diate contact with inhaled allergens and conse-
quently might be involved in the initial events of the
asthmatic response. The number of BAL mast cells is
increased in subjects with asthma and it correlates
with the degree of airway obstruction and
hypersensitivity.
The inflammatory response and mediator release
might influence BHR through the increase of airway
epithelial permeability, the decrease in airway cali-
bre, and the modification of autonomic control or
myogenic function.TM Viral infections and ozone,
which cause reversible damage of the airway epithe-
lium, also result in a transient increase of bronchial
reactivity. 15 Recently, it has been shown that inflam-
mation also occurs in the airways of mildly asthmatic
patients with normal pulmonary function but with
BHR to histamine or methacholine. 16,17
With respect to the ability to induce airway inflam-
mation, the different stimuli can be divided into two
groups. TM The first group includes allergens, occupa-
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tional chemical substances (such as isocyanates), and
certain viral infections which can cause both airway
constriction and airway inflammation. The second
group of stimuli includes histamine, methacholine,
exercise, cold air and hypertonic solutions which are
responsible for a substantial bronchoconstriction.
Airway response to these stimuli is strongly influ-
enced by the degree of pre-existent inflammation.
Allergen inhalation in subjects with asthma causes,
at 10-15 min interval, an early asthmatic response
which is frequently (70% or more in children) fol-
lowed by a late bronchoconstriction that peaks at
6-12 h after the challenge. 19,’ This late asthmatic
response (LAR) is strongly connected with the cellu-
lar phase of airway inflammation, and is particularly
associated with an increase in bronchial reactivity to
histamine and methacholine which may last several
days or weeks. 21-23 We can assume that the increase
of bronchial reactivity to histamine or methacholine
indirectly reflects the degree of airway inflammation
in asthma.
Based on the concept that inflammatory processes
are of paramount importance in modulating bron-
chial reactivity and clinical symptoms, in patients
with chronic asthma it makes sense to use preferen-
tially those drugs that treat the underlying disease
because of their anti-inflammatory activity. Presently,
there is sufficient evidence to suggest that [2-
agonists, anticholinergic drugs and xanthines have
little, if any, anti-inflammatory activity, and that they
have no significant long-term effects on airway reac-
tivity.
’4 On the other hand, drugs with an appreciable
anti-inflammatory activity are already available
(corticosteroids, sodium cromoglycate, nedocromil
sodium) and other anti-inflammatory medications
(cyclosporin, leukotriene antagonists, 5-1ipoxy-
genase inhibitors, platelet activating factor receptor
blockers) are being studied in the treatment of severe
asthma. 25 In the following paragraphs, we will focus
on the role of sodium cromoglycate and nedocromil
sodium in inducing modifications of BHR and of the
underlying inflammatory processes.
Sodium Cromoglycate
Since its discovery, sodium cromoglycate (SCG)
was found to have minimal bronchodilatory effect in
both animal and human models, while it showed
significant activity in modulating inflammatory
events involved in the pathogenesis of allergic dis-
eases. In the past 30 years a large amount of research
has been devoted to the study of the biological and
clinical effects of SCG. Nevertheless, the basic
mechanisms of action of this drug are not completely
understood. 26 At present, there is a reasonable con-
sensus on at least some aspects of the activity of SCG
(Table 1). The first and the most extensively studied
mechanisms are the stabilization of mast cell mem-
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branes and the inhibition of histamine release during
antigen challenge. Very high concentrations of SCG
are required to prevent degranulation of mast cells
from dispersed lung tissue,
iv while concentrations
which are clinically achievable are effective in inhib-
iting BAL mast cell degranulation.
28 This effect on
mast cell degranulation is thought to be dependent
on two main molecular events: blockage of
extracellular calcium shift into the cell and
phosphorylation of specific membrane proteins.
29,3
SCG is also believed to interfere with inflammatory
processes in asthma by inhibiting the activation of
important inflammatory cells, such as eosinophils
and monocytes, and eosinophil chemotaxis induced
by platelet activating factor.1 Finally, prevention
against capsaicin-substance P-induced broncho-
constriction in dogs and bronchospasm caused by
sulphur dioxide, metabisulphites and isocyanates in
human beings, are thought to be due to a blocking
effect on neural reflex bronchoconstriction.2
The effectiveness of SCG in the treatment of child-
hood asthma has been well documented in several
clinical studies. When administered regularly, it de-
creases respiratory symptom scores and the need for
adjunctive anti-asthma medications such as
theophylline, [2-agonists and corticosteroids. Im-
provement in asthma control by SCG is thought to be
largely dependent on its capacity to modulate non-
specific bronchial hyper-responsiveness at therapeu-
tic doses.
For practical purposes, it is useful to analyse the
studies on the effect of SCG on BHR by dividing them
into short-term and long-term studies. In the former,
acute protection is determined by the shift of the
dose-response curve immediately after drug ad-
ministration. In the latter, BHR is measured after
several weeks (or months) of treatment.
TABLE 1. Mechanisms of action of sodium cromoglycate and
nedocromil sodium
Sodium cromoglycate
Stabilization of mast cell membrane
Protein phosphorylation
Inhibition of the activation of inflammatory cells
Inhibition of the effects of cell mediators
Inhibition of neuropeptide-induced neural reflex
bronchoconstriction
Nedocromil sodium
Stabilization of mast cell membrane
Inhibition of mediator release by inflammatory cells
Inhibition of neutrophil and eosinophil chemotaxis induced
by PAF
Inhibition of protein kinase C
Inhibition of neuropeptide release from sensory nerves
(Modified from: Bernstein JA and Berstein IL. Cromolyn and
nedocromil. Novel anti-allergic drugs. Immunol Allergy Clin NAm
1993; 13: 891-902.)Cromoglycate, nedocromil and airway reactivity
SCG inhibits both the early and late phase airway
response when administered before allergen chal-
lenge34 and this is associated with an inhibitory effect
on the allergen-induced hyper-responsiveness.34,5
Administration of SCG after the early response, but at
least 60 min before the late response to allergen,
caused a significant delay of LAR onset and a reduc-
tion in its duration.6 Furthermore, the allergen-
induced increase in methacholine responsiveness
was also prevented.6
Short-term studies which evaluated the protective
effect of SCG against nonantigenic bronchial chal-
lenges showed variable results, depending on the
bronchoprovocative agent utilized. Acute protection
of SCG (40 mg, 10 min before challenge) to
methacholine and histamine was observed by
Woenne et al.7 in 60% of a group of children with
asthma. Mean change in BHR was +1.3 doubling
doses (DD) and 0.8 DD when tested by
methacholine and histamine, respectively. On the
other hand, Cockcroft et al.,8 Griffin et al.9 and
Lemire et al.4 failed to observe any significant pro-
tection of short-term SCG against BHR to histamine
or methacholine.
SCG has a well-documented preventive effect
against bronchoconstriction induced by exercise,41,42
cold air4 and nonisotonic aerosol inhalation.44 SCG
is also more effective than atropine in preventing the
asthmatic response to sulphur dioxide which is me-
diated by atropine-sensitive mechanisms, probably
through irritant airway receptors.45
Long-term studies substantially confirmed the pro-
tective effect of SCG against allergen inhalation chal-
lenge (2-4 weeks of administration)4 and cold air (4
weeks).9 In exercise-induced bronchoconstriction,
the drug effectiveness was unaffected by its chronic
use (1 year).47 The results of chronic dosing of SCG
upon histamine and methacholine challenge were
conflicting when SCG was used for up to 8 weeks.
Lack of activity was reported by some authors,9,4s-5
while positive results--especially for 6 to 8 week
studiesmwere observed by other investigators.
51,5"
Conflicting results disappear when SCG is used
chronically for more than 8 weeks. In such a case, a
significant reduction of BHR, as measured by hista-
mine or methacholine challenge, has been reported
by most authors.3,47,5
Nedocromil sodium
Although nedocromil sodium (NS) differs structur-
ally from SCG, they have many common mechanisms
of action (Table 1). NS reduces both early and late
airway responses to allergen challenge by inhibiting
mediator release from a variety of inflammatory
cells.54 It inhibits histamine secretion from both hu-
man BAL and dispersed lung mast cells, but its
apparent activity varies markedly and inversely with
the strength of the secretory stimulus. 55 NS also inhib-
its the release of PGD2 from human lung mast cells5.
and strongly decreases in vitro neutrophil and
eosinophil mobilization caused by different
chemotactic factors such as PAF and LTB4.
57 In an in
vitro model of human bronchialtissue, NS inhibited
the hyper-responsiveness induced by ionophore ac-
tivated neutrophils presumably by modulating the
release of prostaglandins and/or thromboxane
from inflammatory cells.58 NS also induces a signifi-
cant inhibition of generation of cytotoxic mediators
from both human monocytes and alveolar macro-
phages59 and of the release of leukotrienes and 5-
HETE from alveolar macrophages. In human
neutrophils, a dose-dependent interference with N-
formyl-methionyl-leucyl-phenylalanine (fMLP)-in-
duced superoxide anion production and with fMLP
binding was observed.1,6 Finally, the inhibition of
bronchoconstriction induced by inhaled bradykinin
sulphur dioxide, metabisulphite and ultrasonically
nebulized water suggests that NS prevents
sensitization and activation of airway sensory nerves.
Clinical studies on the use of NS in patients with
asthma have generally demonstrated a beneficial
effect on respiratory symptoms and function similar
to those obtained with SCG. Single-dose studies
confirmed that NS significantly protects against aller-
gen, fog and exercise challenge.4- In exercise-in-
duced bronchoconstriction in children, NS is more
effective than the calcium antagonists verapamil and
ipratropium bromide, but is comparable with SCG.*s
NS seems to offer a better prevention than SCG
against inhaled adenosine.9, sulphur dioxide7 and
cold air.4 Recently, it was shown that in
nonasthmatic, nonatopic subjects, NS administration
for 4 days significantly inhibited a PAF-induced
increase in airway reactivity to methacholine.71 Long-
term (8 weeks) treatment with NS or beclometh-
asone resulted in a comparable decrease of BHR
to methacholine in nonatopic asthmatic adults7"
but, in another study, an 8-week treatment
with beclomethasone was reported to be superior
to treatment with NS with regard to BHR to histamine
and distilled water in atopic asthmatic adults.73 A
decrease in histamine responsiveness was also ob-
served when NS was used for 4 weeks during sea-
sonal allergen exposure74 but no change was re-
ported in 120 clinically stable asthmatic children,
when challenged after NS administration for 8
weeks,75 despite improving pulmonary function in
those with abnormal baseline levels. Finally, experi-
mental data suggest that NS and beclomethasone
probably reduce BHR by different mechanisms.72
This view is supported by the fact that addition of NS
to inhaled corticosteroids can improve clinical symp-
toms and respiratory function76,77 in steroid-depend-
ent adult patients.
Mediators of Inflammation Vol 3 (Supplement) 1994 S17E. A. Valletta and A. L. Boner
Conclusions
Airway inflammation and the release of mediators
from inflammatory cells have recently received atten-
tion as important factors in the pathogenesis of BHR
in asthmatic patients. Consequently, a wider use of
antiallergic drugs for the long-term treatment of
asthma seems advisable. Although there is increasing
recognition that BHR and asthma are not synony-
mous, the capacity of a drug to reduce BHR under
different natural and experimental conditions can be
still considered a useful method to explore its clinical
efficacy. SCG and NS demonstrated, both in vitro and
in vivo, a good antiallergic/anti-inflammatory activity
and they offer protection against various inhalation
challenges, both immunologic and nonimmunologic.
The results of the available studies suggest that SCG
and NS can be safely considered in the choice of a
first-line therapy for the maintenance treatment of
mild-to-moderate asthma.
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